Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;37(6):3028-3038.
doi: 10.1002/hpm.3554. Epub 2022 Aug 18.

Does India need a new pharmaceutical policy? Examining the implications of the drug price control order

Rupali Kumar  1 , Mahika Milind Joshi  1 , Rajat Jagdish Palod  1 , Sreedhar Dharmagadda  2
Affiliations

Does India need a new pharmaceutical policy? Examining the implications of the drug price control order

Rupali Kumar et al. Int J Health Plann Manage. 2022 Nov.

Abstract

Objectives: This article aims to analyse the impact of the pharmaceutical policy on the availability, accessibility and affordability of medicines to the Indian populace. The article delves into the shortcomings of the Drug Price Control Order 2013 and highlights its real-world implications.

Methods: Published literature in the form of scientific articles on the proposed reforms that took place in the pharmaceutical policy was reviewed. The study used the memorandums, laws and government decisions published by the Department of Pharmaceuticals, Ministry of Health and Family Welfare and National Pharmaceutical Pricing Authority|National Pharmaceutical Pricing Authorities.

Results: The pharmaceutical policy in India underwent several changes during 2013-2020 to enhance the affordability and accessibility of drugs. The stringent policy hampered innovation due to the lack of profitability to the Multinational Companies. Moreover, it was found that the impact of the price control order on the low-cost local generic manufacturers affected much of the country's price-sensitive population.

Conclusion: The pharmaceutical policy of India needs to be amended to extend its benefit to its stakeholders. The government should shift its attention to improving the quality of drugs, increasing competition amongst manufacturers and enhancing the accessibility of medicines through state/centre sponsored initiatives.

Keywords: DPCO 2013; National pharmaceutical pricing authority; pharmaceutical policy India; price control order.

PubMed Disclaimer

References

REFERENCES

    1. Fullman N, Yearwood J, Abay SM, et al. Measuring performance on the healthcare access and quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the global burden of disease study 2016. Lancet. 2018;391(10136):2236-2271.
    1. Gronde TV, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: a systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017;12(8):e0182613. Published 2017 Aug 16. https://doi.org/10.1371/journal.pone.0182613
    1. Out-of-pocket Expenditure (% of Current Health Expenditure) - India. Worldbank.org. Accessed November 3, 2021. https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=IN
    1. O’Donnell O, van Doorslaer E, Rannan-Eliya RP, et al. The incidence of public spending on healthcare: comparative evidence from Asia. World Bank Econ Rev. 2007;21(1):93-123. https://doi.org/10.1093/wber/lhl009
    1. Ahmad A, Khan MU, Patel I. Drug pricing policies in one of the largest drug manufacturing nations in the world: are affordability and access a cause for concern? J Res Pharm Pract. 2015;4(1):1-3. https://doi.org/10.4103/2279-042x.150043

LinkOut - more resources